Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
About this item
Full title
Author / Creator
Widmer, N , Decosterd, L A , Leyvraz, S , Duchosal, M A , Rosselet, A , Debiec-Rychter, M , Csajka, C , Biollaz, J and Buclin, T
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). Using a nonlinear mixed effects population model, individual estimates of pharmacokinetic parameters were derived and used to estimate imatinib exposure (area under the curve, AUC) in 58 patients. Plasma-free concentration was d...
Alternative Titles
Full title
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2391118
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2391118
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/sj.bjc.6604355
